HF
SYRE icon

HRT Financial’s Spyre Therapeutics SYRE Stock Holding History

HRT Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$887K Buy
+10,000
New +$730K ﹤0.01% 2240

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

HRT Financial's SYRE Position: Q2 2024 in Review

HRT Financial sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 78,996 shares — an estimated $3M sold.

HRT Financial first reported a position in SYRE in Q4 2022 and held it in 3 quarters. The position peaked at $3M in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • HRT Financial reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HRT Financial sold 78,996 Spyre Therapeutics shares in Q2 2024, an estimated $3M.
  • HRT Financial first reported a position in Spyre Therapeutics in Q4 2022 and held it in 3 quarters.
  • HRT Financial's Spyre Therapeutics position peaked at $3M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.